Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...

An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Houston-based The Normal Anomaly Initiative, a nonprofit with offices in Dallas too that is dedicated to uplifting and ...

“The RFK announcement has kind of scrambled some of the traditional thinking [about] a lot of the people that have been ...